Quarterly ResultMay 15, 2026, 08:07 AM
Indaptus Therapeutics Q1 Net Loss $2.5M; Cash Drops to $1.5M
AI Summary
Indaptus Therapeutics reported Q1 2026 financial results, showing a reduced net loss of $2.5 million compared to $4.5 million in Q1 2025, driven by decreased R&D and G&A expenses. However, the company's cash and cash equivalents significantly declined to $1.5 million from $8.5 million at the end of 2025, with net cash used in operating activities increasing to $7.0 million. Following executive management changes, the company is undergoing a strategic review of its development programs and acknowledges the critical need to raise additional capital.
Key Highlights
- Q1 2026 net loss was $2.5 million, a decrease from $4.5 million in Q1 2025.
- Research and development expenses decreased by $2.3 million to $0.5 million in Q1 2026.
- Cash and cash equivalents dropped to $1.5 million as of March 31, 2026, from $8.5 million on December 31, 2025.
- Net cash used in operating activities increased to $7.0 million in Q1 2026 from $5.0 million in Q1 2025.
- All outstanding Series AA and Series AAA Preferred Stock were converted into common stock during Q1 2026.
- The company is undergoing an executive management transition and a strategic review of its development programs.
- Indaptus Therapeutics needs to raise additional capital to support its business objectives.
Price Impact
More from INDP